Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03779841 · ClinicalTrials.gov registry record · Phase 2
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT03779841 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 323 participants.
The verdict
NCT03779841, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery.
Interventions
- DRUG Placebo
- DRUG AGN-151607
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2023-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03779841
The ClinicalTrials.gov registry entry for NCT03779841 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03779841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03779841 about?
NCT03779841 is a clinical study titled "Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)". This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative Atrial Fibrillation (POAF)...
What is the current status of trial NCT03779841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2019-03-01. Estimated completion is 2023-03-06.
What interventions are being tested in trial NCT03779841?
The interventions under investigation include: Placebo (DRUG), AGN-151607 (DRUG).
Who is sponsoring clinical trial NCT03779841?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.